On September 22, 2025, Ionis Pharmaceuticals announced positive results from a study of zilganersen for Alexander disease, reporting a 33.3% improvement in gait speed against the control group. This marks a significant advancement, as it's the first investigational treatment to show a positive disease-modifying effect in this condition.